25rhk193 10.3205/25rhk193 urn:nbn:de:0183-25rhk1935 Meeting Abstract Claßen Claßen Paul P

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author Meineck Meineck Myriam M

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author Boedecker-Lips Boedecker-Lips Simone Cosima SC

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author Tomalla Tomalla Vanessa V

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author Weinmann Weinmann Arndt A

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, 1. Medizinische Klinik, Mainz

author Saurin Saurin Sabrina S

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author Weinmann-Menke Weinmann-Menke Julia J

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Nephrologie, Rheumatologie und Nierentransplantation (NTX), Mainz

author German Medical Science GMS Publishing House

Düsseldorf

610 20250917 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0627 193 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie 53. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 39. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2025 Vaskulitiden & Kollagenosen Wiesbaden 20250917 20250920 VK.38 TextIntroduction: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor subunit 1, is a novel therapy for systemic lupus erythematosus (SLE). This study aimed to evaluate its real-world effectiveness in patients treated at a German academic tertiary care center.Methods: A prospective observational cohort of 26 SLE patients was analyzed over 24 months. Disease activity, medication use, and adverse events were assessed at baseline and at 3, 6, 9, 12, 18, and 24 months of anifrolumab treatment.Results: Significant reductions in disease activity (SLEDAI-2k, ECLAM) were observed as early as three months after starting anifrolumab. At 12 months, remission as defined by DORIS was achieved in 53% of patients, while lupus low disease activity state (LLDAS) was reached in 89%. Mucocutaneous manifestations responded quickly, alongside significant improvements in fatigue and arthritis/arthralgia. Patients who had previously failed other therapies or had long-standing disease also showed favorable responses. These improvements were accompanied by a reduction in glucocorticoid doses. Anifrolumab was well tolerated, with no significant safety concerns observed during the study period.Conclusion: In this real-world cohort, anifrolumab demonstrated rapid and sustained efficacy in reducing SLE disease activity, with high rates of remission and low disease activity achieved within one year of treatment. The therapy was effective regardless of prior treatments or disease duration and was associated with a reduction in glucocorticoid use. These findings support the use of anifrolumab as a valuable treatment option for patients with active SLE in clinical practice.Confilct of interests: J. W. M., P. C., S. B. L., and M. M. received honoraria from AstraZeneca outside of the scope of the submitted work. 0 0 0 0